The U.S. Cannabis Use Disorder Treatment Market is entering a decisive growth phase as rising cannabis consumption, expanding legalization, and increasing awareness of cannabis-related health risks fuel nationwide demand for structured treatment solutions. From cognitive impairment to withdrawal symptoms and mental health complications linked to long-term use, the recognition of cannabis dependence as a legitimate medical concern is spurring healthcare providers, research institutions, and policymakers to accelerate investments in targeted interventions.
Explore trends before investing – request a sample report today!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16495
Advancements in Treatment Options Strengthen Market Outlook
Across the U.S., accessibility to behavioural and pharmacological therapies is improving, with cognitive behavioural therapy (CBT) remaining the primary mode of treatment. Simultaneously, growing research into pharmacotherapies—such as NAC, cannabidiol (CBD), and emerging medications—continues to broaden the therapeutic landscape. Digital health integration is also reshaping the industry, as telemedicine, remote counselling, and mobile-based recovery tools become essential components of modern treatment models.
Projected 4.7% CAGR Reflects Expanding Adoption
The market is expected to grow at a steady 4.7% CAGR between 2025 and 2035, supported by rising clinical evidence, expansion of mental health infrastructure, and a shift toward early intervention programs. Integrated care models that merge mental health services and addiction treatment are gaining traction, improving patient outcomes while driving market penetration.
U.S. Regional Strength Supported by Reforms and Research
Within North America, the U.S. leads in cannabis addiction treatment adoption, driven by widespread cannabis availability and rising dependency cases. State and federal initiatives supporting mental health and addiction programs are increasing patient access to treatment. Robust telehealth ecosystems also allow providers to reach underserved populations while ongoing research drives development of new therapeutic pathways.
Challenges and Opportunities: From Underdiagnosis to Therapeutic Innovation
Despite progress, underdiagnosis and lingering public misperceptions about the risks of cannabis dependence continue to limit treatment uptake. Many individuals who meet clinical criteria for cannabis use disorder (CUD) remain untreated due to stigma or lack of awareness. However, innovation is rapidly emerging as a major opportunity: AI-enabled therapies, neuroscience-driven drug development, behavioural digital therapeutics, and precision medicine strategies are transforming the outlook for CUD care. These developments are expected to elevate treatment efficiency, reduce relapse risk, and broaden insurer support for CUD services.
Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates –
https://www.futuremarketinsights.com/reports/brochure/rep-gb-16495
Market Evolution: From Early-Stage Recognition to Mainstream Health Integration
Between 2020 and 2024, the cannabis use disorder treatment landscape primarily relied on behavioural programs, with limited medication options and modest digital integration. By contrast, 2025–2035 will usher in a period of stronger regulatory backing, pharmaceutical participation, insurance coverage expansion, and broader acceptance of CUD treatment within primary healthcare settings. Digital therapy platforms, mobile-based CBT tools, and remote coaching solutions are expected to become standard components of care, improving diagnosis rates and treatment continuity.
Country-Level Insights: U.S. Leads Global Progress
The United States is expected to grow at a 5.1% CAGR through 2035—one of the highest globally—reflecting the scale of cannabis consumption, increasing awareness campaigns, and robust rehabilitation networks. Insurance provider participation and government funding further support expanded access to therapy, medication-assisted solutions, and community-based recovery programs.
Strong Growth Across Pharmaceutical and Behavioral Segments
Pharmaceutical interventions targeting cannabinoid receptor modulation and withdrawal symptom management are gaining momentum. Emerging treatments, such as NAC, gabapentin, antidepressants, and cannabinoid receptor-focused medications, are shaping a new wave of pharmacological support. Meanwhile, behavioural therapies—including CBT, CM, and MET—remain essential, reinforced by digital platforms and hybrid care models that improve adherence and access.
Competitive Landscape: Innovation Accelerates Market Advancement
Market leaders such as Indivior PLC, Zynerba Pharmaceuticals, Pfizer, GW Pharmaceuticals (Jazz), and Adial Pharmaceuticals are heavily invested in developing CUD-focused therapies, spanning medication-assisted treatment, cannabinoid-based therapeutics, neuropsychiatric research, and endocannabinoid system modulation. Digital therapeutics companies are also gaining ground, supporting scalable, flexible treatment delivery.
Segmentation Overview
Key segments include treatment types such as detoxification, behavioural therapy, medication, and support groups, along with end users including hospitals, clinics, and rehabilitation centres. The U.S. market spans a broad range of influenced demographics, supported by rising awareness and healthcare integration.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analystsworldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
